Press release | 07 July 2026 MSF calls for inclusion of analogue insulin pens to the Kenyan Social Health Authority benefits package
Statement | 16 June 2026 Europe European Biotech Act Must Deliver Public-Interest Innovation and Equitable Access
Press release | 16 June 2026 Public investment demands public benefits: European Biotech Act must deliver for people
Statement | 18 May 2026 Open-ended Intergovernmental Working Group on the WHO Pandemic Agreement – WHA79/13.3
Statement | 18 May 2026 Follow-up to the political declaration of the high-level meeting of the General Assembly on the prevention and control of non-communicable diseases – WHA79/12.1
Press release | 18 May 2026 Urgent action needed to close devastating vaccination coverage gaps in conflict-affected settings
Press release | 15 May 2026 Countries must lay groundwork to turn Pandemic Agreement commitments into access for all
Press release | 07 July 2026 MSF calls for inclusion of analogue insulin pens to the Kenyan Social Health Authority benefits package
Technical brief | 24 June 2026 The diagnostic blind spot in the 2026 Bundibugyo Ebola disease outbreak: access gaps and priority actions
Statement | 16 June 2026 Europe European Biotech Act Must Deliver Public-Interest Innovation and Equitable Access
Press release | 16 June 2026 Public investment demands public benefits: European Biotech Act must deliver for people
Statement | 18 May 2026 Open-ended Intergovernmental Working Group on the WHO Pandemic Agreement – WHA79/13.3
Statement | 18 May 2026 Follow-up to the political declaration of the high-level meeting of the General Assembly on the prevention and control of non-communicable diseases – WHA79/12.1
Press release | 18 May 2026 Urgent action needed to close devastating vaccination coverage gaps in conflict-affected settings
Press release | 07 July 2026 MSF calls for inclusion of analogue insulin pens to the Kenyan Social Health Authority benefits package
Technical brief | 24 June 2026 The diagnostic blind spot in the 2026 Bundibugyo Ebola disease outbreak: access gaps and priority actions
Statement | 16 June 2026 Europe European Biotech Act Must Deliver Public-Interest Innovation and Equitable Access
Press release | 16 June 2026 Public investment demands public benefits: European Biotech Act must deliver for people
Statement | 18 May 2026 Open-ended Intergovernmental Working Group on the WHO Pandemic Agreement – WHA79/13.3
Statement | 18 May 2026 Follow-up to the political declaration of the high-level meeting of the General Assembly on the prevention and control of non-communicable diseases – WHA79/12.1
Press release | 15 May 2026 Countries must lay groundwork to turn Pandemic Agreement commitments into access for all
Press release | 07 July 2026 MSF calls for inclusion of analogue insulin pens to the Kenyan Social Health Authority benefits package
Technical brief | 24 June 2026 The diagnostic blind spot in the 2026 Bundibugyo Ebola disease outbreak: access gaps and priority actions
Statement | 16 June 2026 Europe European Biotech Act Must Deliver Public-Interest Innovation and Equitable Access
Press release | 16 June 2026 Public investment demands public benefits: European Biotech Act must deliver for people
Statement | 18 May 2026 Open-ended Intergovernmental Working Group on the WHO Pandemic Agreement – WHA79/13.3
Statement | 18 May 2026 Follow-up to the political declaration of the high-level meeting of the General Assembly on the prevention and control of non-communicable diseases – WHA79/12.1
Press release | 18 May 2026 Urgent action needed to close devastating vaccination coverage gaps in conflict-affected settings
Newsletter Newsletter | 03 May 2024 Tuberculosis Sign Our Petition! We need you for our ‘Time for $5’ campaign!
Photo credit: Lana Abramova Letter Letter | 29 April 2024 Diagnostics HIV/AIDS Tuberculosis Letters to Danaher and Cepheid 1 min
Technical brief | 29 April 2024 Pandemic preparedness MSF’s Comments on Selected Provisions of the Proposal for the WHO Pandemic Agreement
Letter | 26 April 2024 Diagnostics Tuberculosis Poland Poland: Institute of Tuberculosis and Lung Diseases writes to Danaher to reduce the price of GeneXpert test
Photograph by Alexandra Sadokova Press release Press release | 25 April 2024 Transparency Research and development Tuberculosis In precedent-setting move towards drug-development cost transparency, MSF reveals cost of its landmark TB clinical trial: €34 million 6 min
Technical brief | 25 April 2024 Transparency Research and development Transparency CORE: Clinical Trial Cost Reporting Toolkit
Photo credit: Marta Soszynska/MSF Press release Press release | 24 April 2024 HIV/AIDS Intellectual property and trade Colombia issues first-ever compulsory license, a landmark step for expanding access to affordable HIV treatment 4 min
